亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Drug discovery based on Alzheimer's disease mutations

总结: Lead Inventors: Iva Greenwald, Ph.D.Problem or Unmet Need:Alzheimer's disease is a devastating disease afflicting millions, and its prevalence is rapidly increasing. Although a number of treatments are available, they function almost exclusively to palliate symptoms, rather than reverse damage or halt disease progression. A number of common and rare genetic mutations have been associated with the disease, and these are promising targets for drug development. In particular, mutations of presenilin 1 and 2 have been associated with familial early-onset AD, inherited in an autosomal dominant manner. In these cases, the alteration of presenilin's function leads to the excessive accumulation of amyloid-beta that is synonymous with AD. The inventors have discovered and characterized two genes, hop-1 and sel-12, in C. elegans that display high homology to human presenilins. The inventors then created mutations in these genes homologous to those that cause AD in humans. These mutations lead to an observable phenotype, constitutive egg-laying. This phenotype can then be utilized as a screening mechanism to identify novel compounds that may be useful in treating AD.

技术优势: Organism-based screen: using a phenotypic screen can identify drug candidates that would be missed in protein target-based screens High-throughput: C. elegans is the multicellular model organisms best suited for high-throughput screening

技术应用: Novel target and biological screen for Alzheimer's drug development Sequence data and antibodies may be useful for development of Alzheimer's diagnostics

详细技术说明: The inventors have discovered and characterized two genes, hop-1 and sel-12, in C. elegans that display high homology to human presenilins. The inventors then created mutations in these genes homologous to those that cause AD in humans. These mutatio...

*Inquiry: Peter Golikov Columbia Technology Ventures Tel: (212) 854-8444 Email: TechTransfer@columbia.edu

*Publications: Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, Sisodia SS, Greenwald I. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci U S A. (1996) Dec 10;93(25):14940-4.

欲了解更多信息，请点击这里